Online inquiry

IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11493MR)

This product GTTS-WQ11493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Colorectal Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11493MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13023MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ4737MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ15794MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ13816MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ7862MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ1889MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ4540MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ9543MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW